Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Monkey wrench thrown at Introgen

WASHINGTON -- Introgen Therapeutics Inc., which filed last week to raise up to $92 million in an IPO, reacted with outrage on Thursday to statements by Rep. Henry Waxman (D-Calif.), who questioned the "high mortality" rate in the company's experimental gene therapy trial in lung cancer patients.

CEO David Nance said Waxman had deliberately "misrepresented the facts in a cynical effort to advance a political agenda"

Read the full 667 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers